Kerendia Approved for Heart Failure With Left Ventricular Ejection Fraction ≥40 Percent

Follow Drugslib on

By Stephanie Brown HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

MONDAY, July 14, 2025 -- Following priority review, the U.S. Food and Drug Administration approved Kerendia (finerenone) for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40 percent.

Kerendia is a nonsteroidal mineralocorticoid receptor antagonist that selectively blocks overactivation of mineralocorticoid receptors in the heart and kidneys. It targets heart failure with LVEF ≥40 percent.

Approval was granted based on the results of a phase 3 trial (FINEARTS-HF), in which Kerendia, added to standard of care, reduced the relative risk for the composite primary end point -- cardiovascular death and total heart failure events -- by 16 percent compared with placebo plus standard of care. Heart failure events were defined as hospitalizations or urgent visits for heart failure. The treatment effect remained consistent across all prespecified subgroups, regardless of whether patients were using sodium-glucose cotransporter 2 inhibitors.

Adverse events reported in ≥1 percent of patients (and more frequently than placebo) were elevated potassium levels, hypotension, abnormally low sodium levels, and events related to worsening kidney function.

"The FDA's approval of finerenone expands treatment options for patients with heart failure with a left ventricular ejection fraction of ≥40 percent -- a large and growing group of patients with a poor prognosis," Chair of the Executive Committee for the FINEARTS-HF study Scott D. Solomon, M.D., from Harvard Medical School and Mass General Brigham in Boston, said in a statement. "Based on the clinical efficacy we saw in the FINEARTS-HF study, finerenone can become a new pillar of comprehensive care."

The approval of Kerendia was granted to Bayer.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-15 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords